RDY – Dr. Reddy’s Laboratories Limited
RDY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.52
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
12.22
Target Price
13.12
Analyst Recom
2.76
Performance Q
Upside
-52.1%
Beta
0.28
Ticker: RDY
No data found
No data found
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-08-06 | RDY | 0 | 1.61 | 0 |
| 2026-08-07 | RDY | 0 | 1.61 | 2.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
1.61
Beta
0.28
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
Growth Score
Sentiment Score
Actual DrawDown %
Max Drawdown 5-Year %
Target Price
13.12
P/E
27.46
Forward P/E
20.56
PEG
1.86
P/S
2.78
P/B
2.51
P/Free Cash Flow
28.39
EPS
0.45
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
10.14
Relative Volume
0.95
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
RDY
Healthcare
$12.22
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
43.1
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-15.7%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-24.1% upside
Upside
-24.1%
RDY — P/E HistoricalDrug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories LtdSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 27527
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
RDY
Latest News
—
Caricamento notizie per RDY…
stock quote shares RDY – Dr. Reddy’s Laboratories Limited Stock Price stock today
news today RDY – Dr. Reddy’s Laboratories Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch RDY – Dr. Reddy’s Laboratories Limited yahoo finance google finance
stock history RDY – Dr. Reddy’s Laboratories Limited invest stock market
stock prices RDY premarket after hours
ticker RDY fair value insiders trading